IMAC - IMAC Holdings completes first cohort of early-stage Parkinson's disease trial

IMAC Holdings ([[IMAC]] +2.9%) announces that it has completed the first cohort of its Phase 1 clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease.The company said it will wait at least 30 days to demonstrate safety of the low dose before initiating the second cohort in which five patients will receive a medium intravenous dose.The first cohort consists of five patients with bradykinesia due to Parkinson’s disease receiving a low dose, intravenous infusion of the stem cell treatment.The Phase 1 clinical trial, consisting of a 15-patient dose escalation safety and tolerability study, will be conducted at three of IMAC’s clinical centers in Chesterfield, Missouri, Paducah, Kentucky, and Brentwood, Tennessee.The trial will be divided into three groups: five patients with bradykinesia due to Parkinson’s disease will receive a low dose, intravenous infusion of stem cells; five will receive a medium intravenous

For further details see:

IMAC Holdings completes first cohort of early-stage Parkinson’s disease trial